lcl161 for primary myelofibrosis: a new therapy in the field
Published 5 years ago • 877 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:51
results for trial of lcl161 for pmf, post-pv mf, and post-et mf patients
-
1:24
final phase 2 results of lcl161 for myelofibrosis
-
1:01
latest advances in myelofibrosis treatment
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
2:01
early myelofibrosis: current treatment approaches and novel strategies
-
4:09
myelofibrosis (rare blood cancer): what are the first symptoms? | the patient story
-
13:48
understanding treatment options for et, pv, and myelofibrosis
-
4:27
viren's journey from blood stem cell transplant patient to survivor
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
1:30
optimal approach to first-line therapy in myelofibrosis
-
2:33
optimizing current treatment approaches in myelofibrosis
-
20:01
primary myelofibrosis - overview (presentation, pathophysiology, investigation, treatment)
-
24:44
primary myelofibrosis
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
3:19
first-line treatment selection in myelofibrosis
-
1:06
origins and treatment options for anemia in myelofibrosis
-
2:15
a phase i study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
-
2:00
novel treatment strategies in myelofibrosis